![](../../files/images/goods/209860-87-7.png)
Tafluprost
CAS No. 209860-87-7
Tafluprost( AFP-168,MK2452 )
Catalog No. M22166 CAS No. 209860-87-7
Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.
Purity : >98% (HPLC)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
![](/themes/theme/en/images/pdf.png)
Size | Price / USD | Stock | Quantity |
2MG | 46 | In Stock |
![]() ![]() |
5MG | 71 | In Stock |
![]() ![]() |
10MG | 87 | In Stock |
![]() ![]() |
25MG | 143 | In Stock |
![]() ![]() |
50MG | 210 | In Stock |
![]() ![]() |
100MG | 311 | In Stock |
![]() ![]() |
500MG | 749 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameTafluprost
-
NoteResearch use only, not for human use.
-
Brief DescriptionTafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern.
-
DescriptionTafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect but also for its good corneal safety profile. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma.
-
In VitroCell Viability Assay Cell Line:RGC Concentration:0.1, 1, 3, 10, 100 μM Incubation Time:48 h Result:Enhanced the viability of these cells in a dose-dependent fashion, with an optimal concentration of 3μM.Increased the relative fluorescence intensity (RFI).
-
In VivoAnimal Model:Male Sprague rat model Dosage:0.0015% Administration:Via eye drops Result:Increased the number of RGCs and reduced the number of TUNEL-positive cells.Animal Model:Prostaglandin receptor deletion C57BL/6 mice model Dosage:3 μL (0.0015% Tafluprost)Administration:Instillation; Single dose Result:Reduced IOP in WT, EP1KO, EP2KO, EP3KO and FPKO mice, and the average IOP reduction rates were 25.8(2.1)%, 26.3(0.8)%, 24.2(1.4)%, 16.5(1.7)% and 20.9(1.5)%, respectively. (The decrease of IOP in EP3KO and FPKO mice was less than that in WT mice.)
-
SynonymsAFP-168,MK2452
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorPGF2α
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number209860-87-7
-
Formula Weight452.53
-
Molecular FormulaC25H34F2O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (552.45 mM)
-
SMILESCC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.
molnova catalog
![](/themes/theme/en/images/ct.png)
![](/themes/theme/en/images/new12.jpg)
![](/themes/theme/en/images/ct2.png)
related products
-
Nestorone
Nestoron2 (ST1435, Elcometrine) is a 19-norprogesterone derivative and steroidal progestin which is used as a hormonal contraceptive, a high-affinity agonist of the progesterone receptor.
-
TG6-129
TG6-129 is an antagonist of the EP2 receptor. TG6-129 suppresses PGE2-induced elevation of cAMP in cells expressing EP2 with an IC50 value of 1.6 μM.
-
ONO-AE3-208
ONO-AE3-208 is an EP4 antagonist. It suppresses cell migration, invasion, and metastasis of prostate cancer.